The Latest
-
Cemile Bingol via Getty Images
The fortunes and flops of pharma M&A
Hindsight offers a better perspective on why some deals are fruitful and others fail.
-
Stock via Getty Images
The weight loss market looks unstoppable. How high could it go?
Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.
-
Stock via Getty Images
3 standout digital innovations in pharma this year
IDEA Pharma just released its Digital Innovation Index. Here are the top companies they identified and some of the standout advances the industry made.
-
Permission granted by Bonum Therapeutics
How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times
John Mulligan, founder of biotechs like Good Therapeutics and Bonum Therapeutics, discusses how biotechs can thrive when the market is against them.
-
Stock via Getty Images
Octave Bioscience is navigating the Parkinson’s labyrinth with Michael J. Fox’s help
A grant from the notorious Parkinson’s foundation has sped up Octave’s timeline to further advance biomarker development in the field.
-
Chip Somodevilla via Getty Images
Deep DivePharma benefited from basing business overseas. An international tax effort could spur a rethink.
U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.
-
Permission granted by AstraZeneca
Q&AThe head of AstraZeneca’s new digital health business on how the pharma is leveraging tech
Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.
-
Getty Images via Getty Images
Biopharma’s top 5 IPOs of 2023 (so far)
Despite one major outlier, 2023’s IPOs haven’t hit the heights of the past three years.
-
Stock via Getty Images
As alcohol-related deaths climb, new drugs could curb the urge to drink
A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.
-
Permission granted by EMD Serono
How EMD Serono plans to hit its lofty goals in R&D
The company’s global heads of oncology R&D reveal how strategic partnerships are key to its launch plans following layoffs in the U.S.
-
Permission granted by Organon
Q&A // First 90 DaysOrganon’s chief medical officer wants to change how the world sees women’s health
Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.
-
iStock via Getty Images
The biopharma COO’s playbook
Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.
-
Stock via Getty Images
Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs
Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.
-
Stock via Getty Images
A startling drop in U.S. life expectancy — and how pharma could help turn the tide
The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.
-
Chip Somodevilla via Getty Images
Top FDA official Woodcock to retire early next year
The 37-year veteran helmed the agency’s pandemic response, and was a key decision-maker in controversial calls on opioids, an Alzheimer's therapy and muscular dystrophy drugs.
-
Permission granted by AstraZeneca/U. of Birmingham
Q&AAstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?
Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.
-
iStock via Getty Images
The power of genomics-based healthcare remains largely untapped
23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.
-
Permission granted by Talus Bio
Biotech SpotlightA biotech tackles drug discovery with transcription factor know-how
Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.
-
Permission granted by Johnson & Johnson Innovative Medicine
6 ways to improve clinical trial diversity — as shown by J&J
Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.
-
Courtesy of Sarepta
Can Sarepta’s Duchenne gene therapy still deliver on its promise?
For Sarepta — and DMD patients — there’s a lot riding on the treatment’s next steps.
-
Stock via Getty Images
Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.
The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.
-
Stock via Getty Images
5 of the best paid biopharma CEOs
As revenue growth remained high last year, so did biopharma CEO pay in the U.S.
-
Photo illustration: Industry Dive
The 2023 Red Jacket honorees
This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.
-
Permission granted by BioMarin
Making MovesDoes BioMarin’s CEO shuffle signal bigger changes ahead?
With its long-time CEO on the way out, the rare disease biotech has seen an activist investor grow its stake.
-
zennie via Getty Images
How pharma leaders talk about ethics in a highly criticized industry
The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?
